Health, Food, and Drug Law

Harvard Law Professor Glenn Cohen shares how artificial intelligence is changing medicine — and how the law can adapt.

Health law policy expert Glenn Cohen says the biotech firm’s uncertain future shows the need for protections of personal and genetic info.

The psychic and political toll of the pandemic is examined at a Petrie-Flom book event.

Health law expert Carmel Shachar discusses the rapidly evolving legal issues around telehealth care delivered across state lines.

A Harvard Law School visiting professor says that increasing competition could lower the cost of medications for millions of Americans.

At a Petrie-Flom Center book talk, panelists discussed the lost history of constitutional challenges to punitive drug laws and possible ways forward.

Harvard Law alum and M.D. Daniel G. Aaron says that there is danger the Court could “shore back the power of administrative agencies.”

Harvard Law’s Emily Broad Leib explains why the FDA is considering new front-of-package labels to call out foods with high fat, salt, and sugar.

I. Glenn Cohen ’03, the James A. Attwood and Leslie Williams Professor of Law and a deputy dean at Harvard Law School, has been elected a member of the prestigious National Academy of Medicine.

Food law and policy expert Emily Broad Leib discusses why doctors need to know more about food and nutrition.

Experts from law, philosophy, and spiritual care discuss issues surrounding research and the safer use of psychedelics, kicking off a Divinity School initiative.

Despite promise of success stories from patients in recovery, a Harvard Law School panel cautions that research is lacking on benefits vs. risks of using psychedelics in addiction treatment.

Harvard Law's Center for Health Law and Policy Innovation represents five families challenging a Louisiana ban on gender-affirming care for transgender minors.

Experts cite the complexity of the problem of homelessness, which is rooted in poverty and lack of affordable housing, but includes medical, psychiatric and substance-use issues.

Psychedelic drugs show promise as a new treatment option for some psychiatric maladies, but experts see a possible state and federal legal clash.

Harvard Law School Professor Ruth Okediji says that while the Biden administration’s proposal to use federal ‘march-in’ rights to lower drug costs is an important development, it may be more a signal than the initiation of a workable plan.

Harvard Law expert Erika Hanson argues that providing direct cash supports to low-income families experiencing a medical crisis improves health outcomes.

Harvard Law Professor Carmel Shachar explains the federal government’s effort to loosen marijuana regulations and argues the 1970s restrictions were always misguided.